RT Journal Article SR Electronic T1 Against all odds: anti-IgE for intrinsic asthma? JF Thorax JO Thorax FD BMJ Publishing Group Ltd and British Thoracic Society SP 94 OP 96 DO 10.1136/thoraxjnl-2013-203738 VO 69 IS 1 A1 Marek Lommatzsch A1 Stephanie Korn A1 Roland Buhl A1 Johann Christian Virchow YR 2014 UL http://thorax.bmj.com/content/69/1/94.abstract AB For many years, pathogenetic concepts and the results of clinical trials supported the view that anti-IgE treatment is specifically effective in allergic asthma. However, there is now growing clinical and mechanistic evidence suggesting that treatment with the anti-IgE antibody omalizumab can be effective in patients with intrinsic asthma. Therefore, large and well-controlled clinical trials with anti-IgE are urgently warranted in patients with intrinsic asthma. In addition, there is a need to find new biomarkers which can identify patients with asthma who respond to anti-IgE treatment.